PB
Therapeutic Areas
MiNK Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| MiNK-101 | Relapsed/Refractory Solid Tumors | Phase 1 |
| MiNK-201 | Acute Respiratory Distress Syndrome (ARDS) | Phase 1b/2 |
| CAR-iNKT Programs | Hematological and Solid Tumors | Preclinical |
Leadership Team at MiNK Therapeutics
JB
Jennifer Buell, Ph.D.
President and Chief Executive Officer
GA
Garo Armen, Ph.D.
Chairman of the Board
MV
Marc van Dijk, Ph.D.
Scientific Advisor (Former CSO)
RS
Robert Stein, M.D., Ph.D.
Scientific Advisor
MH
Manuel Hidalgo, M.D., Ph.D.
Scientific Advisor
ME
Mark Exley, Ph.D.
Scientific Advisor
JG
Jenny Gumperz, Ph.D.
Scientific Advisor
LL
Lydia Lynch, Ph.D.
Scientific Advisor
MM
Marcela Maus, M.D., Ph.D.
Scientific Advisor
BC
Brian Corvese
Director